Aptevo Therapeutics announces CEO transition effective April
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
February 3, 2026 8:05 AM ESTClinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond
SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced executive leadership transitions to support the Company's continued execution, drive achievement of long-term strategic objectives, and next phase of growth.
Effective April 1, 2026, Marvin White, who has served as President and Chief... More
